Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

SCI Pharmtech Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

22 Aug 2015 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - SCI Pharmtech Inc (4119-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

28 Aug 2015 Thomson Reuters Stock Report 11 $25.00

SCI Pharmtech (4119 TT): Upward Revision of Major Product Shipments

We notice that U.S. FDA strictly controls API resources, and has withdrawn licenses from many low cost Chinese and Indian API...

04 Aug 2015 MasterLink Securities Corporation 6 $58.00

Wright Investors Service Comprehensive Report for Sci Pharmtech Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

04 Aug 2015 Wright Reports 56 $75.00

旭富 (4119):主力產品關節炎與抗發炎藥出貨量上修

元富觀察,美國FDA從嚴管控原料藥來源,不少低價的中國及印度原料藥廠被FDA撤銷資格,而旭富原為瑞士藥廠 Siegfried之台灣子公司,承襲其嚴謹的生產規範,陸續取得國際客戶的訂單,且旭富2015年獲利結構優化,營收、獲利將創歷史新高,2016年則...

29 Jul 2015 MasterLink Securities Corporation 5 $35.00

SCI Pharmtech, Inc. (4119) - Financial Analysis Review

SCI Pharmtech, Inc. (4119) - Financial Analysis Review Summary SCI Pharmtech, Inc. (SCI) is a pharmaceutical company th...

21 Jul 2015 GlobalData 26 $125.00

SCI Pharmtech (4119 TT): Both Sales and Profit to Break Records in 2015

Our sales forecast for 2015 is NT$1.8bn, +20% YoY, with GM up by 3ppt to 35%. We revise up EPS to NT$4.83 from NT$4.46 as hig...

25 May 2015 MasterLink Securities Corporation 6 $58.00

旭富 (4119);2015年營收、獲利將創歷史新高

旭富2015年營收18億元,YOY +20%,毛利率將增加3%至35%,因高毛利率的風濕性關節炎與抗憂鬱藥佔比增加,且抗發炎藥毛利率改善,EPS 亦從4.46元上修至4.83元。元富觀察,美國FDA從嚴管控原料藥來源,不少低價的中國及印度原料藥廠紛紛...

21 May 2015 MasterLink Securities Corporation 5 $35.00

SCI Pharmtech, Inc. (4119) - Financial Analysis Review

SCI Pharmtech, Inc. (4119) - Financial Analysis Review Summary SCI Pharmtech, Inc. (SCI) is a pharmaceutical company. T...

14 May 2015 GlobalData 25 $125.00

SCI Pharmtech, Inc. (4119) - Financial Analysis Review

SCI Pharmtech, Inc. (4119) - Financial Analysis Review Summary SCI Pharmtech, Inc. (SCI) is a pharmaceutical company. T...

12 Feb 2015 GlobalData 25 $125.00